MediGene sells European Eligard rights to Astellas
This article was originally published in Scrip
Executive Summary
MediGene of Germany has sold the full European marketing and distribution rights to its prostate cancer treatment Eligard (leuprolide acetate) to current partner Astellas Pharma Europe for €25 million in cash plus future royalties.